|
ML Laboratories is to acquire Quadrant Technologies, the Nottingham-based pulmonary drug delivery specialist with 35 staff, for £47m, and has also announced plans to change its name to Innovata. 17-Jun-2005 ML Laboratories is to consolidate its pharmaceutical operations onto a single site in St Albans, with the closure of sites in Liverpool, Warrington, Tewkesbury, Keele and Leicester and the loss of about 65 jobs. 26-Apr-2005 ML Laboratories has sold Healthcare Education Services, the St Albans-based provider of pharmaceutical industry training services with annual turnover of £1.2m, to Bridgehead Pharmalicensing Group. 10-Feb-2004 ML Laboratories is planning to raise £14m in a share issue, in order to recapitalise its business following a delay to a number of drug licensing deals. 29-Jan-2004 ML Laboratories is to sell its Icodextrin glucose polymer manufacturing business in Liverpool to Baxter Healthcare for £6.5m. 25-Mar-2003 ML Laboratories is planning to float the manufacturing operations of its Cobra Therapeutics division, in order to raise a few million pounds. 30-Apr-2002 ML Laboratories is planning to sell off its non-core activities - including the Innovata Biomed inhaler business and the DNA production division of its Cobra subsidiary - in order to focus on cancer treatment and pain management. 30-Jan-2002 ML Laboratories has raised £17m from Paul Capital Royalty to fund US clinical trials of Adept, a new drug that reduces surgical adhesions. 10-Jul-2001 ML Laboratories has raised £11m in a share placing in order to fund the development of its drug delivery business. 26-Jul-2000 ML Laboratories is acquiring Cobra, the gene therapy company, for an initial £8m. 10-Feb-2000 ML Laboratories is in negotiations to acquire Cobra Therapeutics, the Keele-based gene therapy company, for about £15m. 01-Feb-2000 ML Laboratories is planning to float a stake of up to 25% in its Innovata Biomed respiratory products division. 26-Jan-2000 ML Laboratories has awarded US commercial rights for its Viraldon Aids treatment to General Medical Industries. 23-Feb-1999 ML Laboratories hopes to start selling its Icodial renal dialysis treatment in the US by 2000, as its licensee Baxter Healthcare is applying for US marketing approval. 25-Jun-1998 ML Laboratories has won approval from the Medicines Control Agency to use the salbutamol asthma drug in its dry powder inhaler. 10-Jul-1996 Proteus International and ML Laboratories have agreed to co-operate in the development of a prostate and breast cancer treatment. 29-Mar-1996 ML Laboratories plans an institutional placing to generate £25m for development. 26-Jan-1996 ML Laboratories plans to apply for a licence for its anti-Aids drug in 1996, as trials continue. 06-Sep-1995
|